Literature DB >> 18971283

HLA-associated alterations in replication capacity of chimeric NL4-3 viruses carrying gag-protease from elite controllers of human immunodeficiency virus type 1.

Toshiyuki Miura1, Mark A Brockman, Zabrina L Brumme, Chanson J Brumme, Florencia Pereyra, Alicja Trocha, Brian L Block, Arne Schneidewind, Todd M Allen, David Heckerman, Bruce D Walker.   

Abstract

Human immunodeficiency virus type 1 (HIV-1)-infected persons who maintain plasma viral loads of <50 copies RNA/ml without treatment have been termed elite controllers (EC). Factors contributing to durable control of HIV in EC are unknown, but an HLA-dependent mechanism is suggested by overrepresentation of "protective" class I alleles, such as B*27, B*51, and B*57. Here we investigated the relative replication capacity of viruses (VRC) obtained from EC (n = 54) compared to those from chronic progressors (CP; n = 41) by constructing chimeric viruses using patient-derived gag-protease sequences amplified from plasma HIV RNA and inserted into an NL4-3 backbone. The chimeric viruses generated from EC displayed lower VRC than did viruses from CP (P < 0.0001). HLA-B*57 was associated with lower VRC (P = 0.0002) than were other alleles in both EC and CP groups. Chimeric viruses from B*57(+) EC (n = 18) demonstrated lower VRC than did viruses from B*57(+) CP (n = 8, P = 0.0245). Differences in VRC between EC and CP were also observed for viruses obtained from individuals expressing no described "protective" alleles (P = 0.0065). Intriguingly, two common HLA alleles, A*02 and B*07, were associated with higher VRC (P = 0.0140 and 0.0097, respectively), and there was no difference in VRC between EC and CP sharing these common HLA alleles. These findings indicate that cytotoxic T-lymphocyte (CTL) selection pressure on gag-protease alters VRC, and HIV-specific CTLs inducing escape mutations with fitness costs in this region may be important for strict viremia control in EC of HIV.

Entities:  

Mesh:

Substances:

Year:  2008        PMID: 18971283      PMCID: PMC2612337          DOI: 10.1128/JVI.01471-08

Source DB:  PubMed          Journal:  J Virol        ISSN: 0022-538X            Impact factor:   5.103


  44 in total

1.  CD8 CTL responses in vaccines: emerging patterns of HLA restriction and epitope recognition.

Authors:  G Ferrari; W Neal; A Jones; N Olender; J Ottinger; R Ha; M J McElrath; P Goepfert; K J Weinhold
Journal:  Immunol Lett       Date:  2001-11-01       Impact factor: 3.685

2.  Statistical significance for genomewide studies.

Authors:  John D Storey; Robert Tibshirani
Journal:  Proc Natl Acad Sci U S A       Date:  2003-07-25       Impact factor: 11.205

3.  A dual infection/competition assay shows a correlation between ex vivo human immunodeficiency virus type 1 fitness and disease progression.

Authors:  M E Quiñones-Mateu; S C Ball; A J Marozsan; V S Torre; J L Albright; G Vanham; G van Der Groen; R L Colebunders; E J Arts
Journal:  J Virol       Date:  2000-10       Impact factor: 5.103

4.  Analysis of the frequencies of HLA-A, B, and C alleles and haplotypes in the five major ethnic groups of the United States reveals high levels of diversity in these loci and contrasting distribution patterns in these populations.

Authors:  K Cao; J Hollenbach; X Shi; W Shi; M Chopek; M A Fernández-Viña
Journal:  Hum Immunol       Date:  2001-09       Impact factor: 2.850

5.  Genetic characterization of human immunodeficiency virus type 1 in elite controllers: lack of gross genetic defects or common amino acid changes.

Authors:  Toshiyuki Miura; Mark A Brockman; Chanson J Brumme; Zabrina L Brumme; Jonathan M Carlson; Florencia Pereyra; Alicja Trocha; Marylyn M Addo; Brian L Block; Alissa C Rothchild; Brett M Baker; Theresa Flynn; Arne Schneidewind; Bin Li; Yaoyu E Wang; David Heckerman; Todd M Allen; Bruce D Walker
Journal:  J Virol       Date:  2008-06-18       Impact factor: 5.103

6.  Role of the human immunodeficiency virus type 1 envelope gene in viral fitness.

Authors:  Hector R Rangel; Jan Weber; Bikram Chakraborty; Arantxa Gutierrez; Michael L Marotta; Muneer Mirza; Patti Kiser; Miguel A Martinez; Jose A Este; Miguel E Quiñones-Mateu
Journal:  J Virol       Date:  2003-08       Impact factor: 5.103

7.  Central role of reverting mutations in HLA associations with human immunodeficiency virus set point.

Authors:  Philippa C Matthews; Andrew Prendergast; Alasdair Leslie; Hayley Crawford; Rebecca Payne; Christine Rousseau; Morgane Rolland; Isobella Honeyborne; Jonathan Carlson; Carl Kadie; Christian Brander; Karen Bishop; Nonkululeko Mlotshwa; James I Mullins; Hoosen Coovadia; Thumbi Ndung'u; Bruce D Walker; David Heckerman; Philip J R Goulder
Journal:  J Virol       Date:  2008-07-02       Impact factor: 5.103

8.  HIV evolution: CTL escape mutation and reversion after transmission.

Authors:  A J Leslie; K J Pfafferott; P Chetty; R Draenert; M M Addo; M Feeney; Y Tang; E C Holmes; T Allen; J G Prado; M Altfeld; C Brander; C Dixon; D Ramduth; P Jeena; S A Thomas; A St John; T A Roach; B Kupfer; G Luzzi; A Edwards; G Taylor; H Lyall; G Tudor-Williams; V Novelli; J Martinez-Picado; P Kiepiela; B D Walker; P J R Goulder
Journal:  Nat Med       Date:  2004-02-08       Impact factor: 53.440

9.  Comparing the ex vivo fitness of CCR5-tropic human immunodeficiency virus type 1 isolates of subtypes B and C.

Authors:  Sarah C Ball; Awet Abraha; Kalonji R Collins; Andre J Marozsan; Heather Baird; Miguel E Quiñones-Mateu; Adam Penn-Nicholson; Michael Murray; Nathalie Richard; Michael Lobritz; Peter A Zimmerman; Tatsuyoshi Kawamura; Andrew Blauvelt; Eric J Arts
Journal:  J Virol       Date:  2003-01       Impact factor: 5.103

10.  Clustered mutations in HIV-1 gag are consistently required for escape from HLA-B27-restricted cytotoxic T lymphocyte responses.

Authors:  A D Kelleher; C Long; E C Holmes; R L Allen; J Wilson; C Conlon; C Workman; S Shaunak; K Olson; P Goulder; C Brander; G Ogg; J S Sullivan; W Dyer; I Jones; A J McMichael; S Rowland-Jones; R E Phillips
Journal:  J Exp Med       Date:  2001-02-05       Impact factor: 14.307

View more
  79 in total

1.  Impact of HLA-B*81-associated mutations in HIV-1 Gag on viral replication capacity.

Authors:  Jaclyn K Wright; Vanessa L Naidoo; Zabrina L Brumme; Jessica L Prince; Daniel T Claiborne; Philip J R Goulder; Mark A Brockman; Eric Hunter; Thumbi Ndung'u
Journal:  J Virol       Date:  2012-01-11       Impact factor: 5.103

2.  Lack of association between HLA class II alleles and in vitro replication capacities of recombinant viruses encoding HIV-1 subtype C Gag-protease from chronically infected individuals.

Authors:  Jaclyn K Wright; Zabrina L Brumme; Boris Julg; Mary van der Stok; Zenele Mncube; Xiaojiang Gao; Jonathan M Carlson; Philip J R Goulder; Bruce D Walker; Mark A Brockman; Thumbi Ndung'u
Journal:  J Virol       Date:  2011-11-16       Impact factor: 5.103

3.  Uncommon pathways of immune escape attenuate HIV-1 integrase replication capacity.

Authors:  Mark A Brockman; Denis R Chopera; Alex Olvera; Chanson J Brumme; Jennifer Sela; Tristan J Markle; Eric Martin; Jonathan M Carlson; Anh Q Le; Rachel McGovern; Peter K Cheung; Anthony D Kelleher; Heiko Jessen; Martin Markowitz; Eric Rosenberg; Nicole Frahm; Jorge Sanchez; Simon Mallal; Mina John; P Richard Harrigan; David Heckerman; Christian Brander; Bruce D Walker; Zabrina L Brumme
Journal:  J Virol       Date:  2012-04-11       Impact factor: 5.103

4.  Changes in function of HIV-specific T-cell responses with increasing time from infection.

Authors:  Michel L Ndongala; Philomena Kamya; Salix Boulet; Yoav Peretz; Danielle Rouleau; Cécile Tremblay; Roger Leblanc; Pierre Côté; Jean-Guy Baril; RéJean Thomas; Sylvie Vézina; Mohamed R Boulassel; Jean-Pierre Routy; Rafick P Sékaly; Nicole F Bernard
Journal:  Viral Immunol       Date:  2010-04       Impact factor: 2.257

5.  Impaired replication capacity of acute/early viruses in persons who become HIV controllers.

Authors:  Toshiyuki Miura; Zabrina L Brumme; Mark A Brockman; Pamela Rosato; Jennifer Sela; Chanson J Brumme; Florencia Pereyra; Daniel E Kaufmann; Alicja Trocha; Brian L Block; Eric S Daar; Elizabeth Connick; Heiko Jessen; Anthony D Kelleher; Eric Rosenberg; Martin Markowitz; Kim Schafer; Florin Vaida; Aikichi Iwamoto; Susan Little; Bruce D Walker
Journal:  J Virol       Date:  2010-05-26       Impact factor: 5.103

6.  The Breadth of Expandable Memory CD8+ T Cells Inversely Correlates with Residual Viral Loads in HIV Elite Controllers.

Authors:  Zaza M Ndhlovu; Eleni Stampouloglou; Kevin Cesa; Orestes Mavrothalassitis; Donna Marie Alvino; Jonathan Z Li; Shannon Wilton; Daniel Karel; Alicja Piechocka-Trocha; Huabiao Chen; Florencia Pereyra; Bruce D Walker
Journal:  J Virol       Date:  2015-08-12       Impact factor: 5.103

Review 7.  HIV-specific CD8⁺ T cells and HIV eradication.

Authors:  R Brad Jones; Bruce D Walker
Journal:  J Clin Invest       Date:  2016-01-05       Impact factor: 14.808

8.  Influence of Gag-protease-mediated replication capacity on disease progression in individuals recently infected with HIV-1 subtype C.

Authors:  Jaclyn K Wright; Vladimir Novitsky; Mark A Brockman; Zabrina L Brumme; Chanson J Brumme; Jonathan M Carlson; David Heckerman; Bingxia Wang; Elena Losina; Mopo Leshwedi; Mary van der Stok; Lungile Maphumulo; Nompumelelo Mkhwanazi; Fundisiwe Chonco; Philip J R Goulder; Max Essex; Bruce D Walker; Thumbi Ndung'u
Journal:  J Virol       Date:  2011-02-02       Impact factor: 5.103

9.  Replication Capacity of Viruses from Acute Infection Drives HIV-1 Disease Progression.

Authors:  Philippe Selhorst; Carina Combrinck; Nonkululeko Ndabambi; Sherazaan D Ismail; Melissa-Rose Abrahams; Miguel Lacerda; Natasha Samsunder; Nigel Garrett; Quarraisha Abdool Karim; Salim S Abdool Karim; Carolyn Williamson
Journal:  J Virol       Date:  2017-03-29       Impact factor: 5.103

10.  HLA-associated viral mutations are common in human immunodeficiency virus type 1 elite controllers.

Authors:  Toshiyuki Miura; Chanson J Brumme; Mark A Brockman; Zabrina L Brumme; Florencia Pereyra; Brian L Block; Alicja Trocha; Mina John; Simon Mallal; P Richard Harrigan; Bruce D Walker
Journal:  J Virol       Date:  2009-01-19       Impact factor: 5.103

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.